Targeting histone deacetylase-3 blocked epithelial-mesenchymal plasticity and metastatic dissemination in gastric cancer
Journal
Cell Biology and Toxicology
Journal Volume
39
Pages
1873–1896
Date Issued
2022-01-01
Author(s)
Wu, Sheng-Mao
Jan, Yee-Jee
Tsai, Shih-Chuan
Pan, Hung-Chuan
Shen, Chin-Chang
Yang, Cheng-Ning
Lee, Shu-Hua
Shen, Li-Wei
Chiu, Chien-Shan
Arbiser, Jack L
Meng, Menghsiao
Sheu, Meei-Ling
Abstract
Histone deacetylase (HDAC) inhibitors (HDIs) can modulate the epithelial-mesenchymal transition (EMT) progression and inhibit the migration and invasion of cancer cells. Emerging as a novel class of anti-cancer drugs, HDIs are attracted much attention in the field of drug discovery. This study aimed to discern the underlying mechanisms of Honokiol in preventing the metastatic dissemination of gastric cancer cells by inhibiting HDAC3 activity/expression.
Subjects
Endoplasmic reticulum stress; Epithelial–mesenchymal transition; Histone deacetylase 3; Histone deacetylase inhibitors; Peritoneal dissemination
SDGs
Publisher
SPRINGER
Type
journal article